Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies Want New US FDA Council To Help Resolve Inter-Agency Combo Product Disputes

Executive Summary

A range of topics were raised in feedback provided by industry groups to FDA about what the priorities should be for the agency's new Combination Products Policy Council, but addressing inter-center disagreements was a repeat concern. Also raised: misaligned communication policies; pediatric combo-product reviews; and implementation of the 21st Century Cures Act.

You may also be interested in...



Guidance To Put More Combo Products Into Device Realm Due Out In Fall, FDA Commish Gottlieb Tells Congress

A combination products guidance “to move more products into the device realm” will be released either at the end of this summer or in early fall, US FDA Commissioner Scott Gottlieb told lawmakers at a hearing. He also explained how new 21st Century Cures authority to hire biomedical scientists with very specific expertise will help the agency.

US FDA: 510(k)-Exempt Class II Devices Should Withdraw Applications

In line with the 21st Century Cures Act, US FDA has finalized a list of class II devices that will no longer need pre-market notification to get to market. Also, check out our updated Cures Act implementation table.

US FDA Faces Down Complex Combo Products, Fires Up Oncology Center Of Excellence

FDA officials discuss difficulties dealing with complex combination products, the future of the agency's product centers, and promotion of industry collaboration at the Drug Information Association's annual meeting.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel